VivoSeq
Oncology

Acute Myeloid Leukemia

653

Pipeline Programs↗

289

Active Trials↗

176

Companies Involved↗

Acute Myeloid Leukemia is a highly competitive landscape with 653 programs across 176 companies. The most active players are Kyowa Kirin Co., Ltd., Lomond Therapeutics Holdings, Inc., CSL Behring. 35 therapies are approved with 88 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

75/100

Mech. Concentration

5/100

Completion Rate

66/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Kyowa Kirin Co., Ltd. logo

Kyowa Kirin Co., Ltd.

6 programs

Phase 1L

Lomond Therapeutics Holdings, Inc.

4 programs

Phase 1CSL Behring logo

CSL Behring

2 programs

Phase 1Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd.

2 programs

Phase 1Otsuka logo

Otsuka

1 program

Phase 1B

Base Therapeutics (Shanghai) Co., Ltd.

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical25

Dasatinib

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Sargramostim

Sanofi

Chidamide

Chipscreen Biosciences, Ltd.

Rhtpo

Shandong University

EP0042

Ellipses Pharma

Phase 1247

Pemigatinib

Incyte

Regorafenib

Bayer

Ponatinib

Takeda

Dovitinib

Novartis

Ixazomib Citrate

Takeda

Phase 2258

Tisagenlecleucel

Novartis

Aldesleukin

Iovance Biotherapeutics, Inc.

Gemtuzumab Ozogamicin

Wyeth-Lederle Vaccines

Nilotinib

Azurity Pharmaceuticals

Gilteritinib

Astellas

Phase 388

Alemtuzumab

Genzyme, a Sanofi Company

Epoetin Alfa

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Mitoxantrone Hydrochloride

Pfizer

Mitoxantrone

EMD Serono

Daunorubicin

Hikma Pharmaceuticals LLC

Approved35

Decitabine

Sun Pharma

Venetoclax

AbbVie

Deferasirox

Novartis

Azathioprine

Legacy Health System

Acetylcysteine

Arbor Pharmaceuticals, Inc.

Analysis

Modality Breakdown

81%

Small molecule

587 of 721 classified programs — the dominant modality here.

19%ALL OTHERSCell therapy689%Monoclonal antibody304%Protein / enzyme182%Vaccine6<1%Antibody–drug conjugate5<1%Peptide4<1%Other3<1%

Small molecule leads; the ring shows all 721 classified programs, each share of the total. Modality classified for 98% of 805 pipeline programs.

Analysis

Trial Status

997

clinical trials

Completed401 · 40%
Recruiting158 · 16%
Terminated156 · 16%
Unknown status97 · 10%
Active, not recruiting79 · 8%
Not yet recruiting49 · 5%
Other57 · 6%

Clinical Trials

Trial Activity

997 trials

BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Recruiting·—·Phase 1/2·NCT06746519·135 enrolled
Venetoclax + Azacitidine in Patients With Acute Myeloid Leukemia
Recruiting·GGrupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias·Phase 2·NCT06668558·29 enrolled
Targeting Acute Myeloid Leukemia Immunosuppressive Microenvironment by combinedIDO1 Inhibition and PD-1 Blockade
Recruiting·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·N/A·NCT06874257·20 enrolled
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Recruiting·SSillaJen, Inc.·Phase 1·NCT05768932·260 enrolled
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06541444·9 enrolled
A Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06618001·115 enrolled
Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation
Recruiting·TTechnische Universität Dresden·Phase 2·NCT06717958·76 enrolled
FHD-286 With Low-Dose Weekly Decitabine/Venetoclax in Patients With Acute Myeloid Leukemia
Recruiting·MMontefiore Medical Center·Phase 1·NCT07283094·33 enrolled
Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE
Recruiting·IInstitut Paoli-Calmettes·Phase 2·NCT06055621·35 enrolled
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
Recruiting·—·Phase 3·NCT06990321·68 enrolled
Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·HHrain Biotechnology Co., Ltd.·Phase 1·NCT06760260·7 enrolled
Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06541405·9 enrolled
Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT06769490·44 enrolled
Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results
Recruiting·SShanghai Tong Ren Hospital·Phase 2·NCT05736978·58 enrolled
The Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation in Newly Diagnosed High-relapse-risk CEBPA Mutant Acute Myeloid Leukemia
Recruiting·RRuijin Hospital·N/A·NCT06458257·50 enrolled
Page 1 of 67

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)